Paris, France, November 24, 2023 - eureKING (ISIN: FR0014009ON9, Euronext Paris, the "Company"), the first European special purpose acquisition company ("SPAC") in healthcare dedicated to bioproduction, announces the proposed timetable regarding the delisting of all financial instruments issued by the Company in the event of the approval by the shareholders of the early dissolution of the Company at the extraordinary general meeting to be held on November 28.
The shareholders of eureKING are called to approve the early dissolution of the Company at the extraordinary general meeting to be held on November 28, 2023 (the "Extraordinary General Meeting"). At the same meeting, shareholders will also be asked to vote on the acknowledgment that the Founders' Warrants (BSAR A) and Market Warrants (BSAR B) have lapsed, in accordance with their terms and conditions and on the delisting of the Company's financial instruments admitted to trading on the regulated market of Euronext Paris.
In the absence of an Initial Business Combination on the Initial Business Combination Deadline1, the Founders' Warrants (BSAR A) and the Market Warrants (BSAR B) will be definitively deprived of any right of exercise and will expire worthless in the context of the forthcoming liquidation, if approved by the shareholders, in accordance with their respective terms and conditions, the Company's articles of association and the IPO Prospectus.
As a result of the Company's early dissolution, and assuming a favourable vote by the shareholders, (i) the listing of the Market Warrants (BSAR B) and the Market Shares (actions de préférence de catégorie B) will be suspended as from November 28, 2023, and (ii) the Market Warrants (BSAR B) and the Market Shares (actions de préférence de catégorie B) will be delisted from the regulated market by Euronext Paris as of November 29, 2023, it being specified that the Market Shares (actions de préférence de catégorie B) will remain admitted to Euroclear France. Therefore, as from this date, no further financial instruments of the Company will be admitted to trading on Euronext Paris.
MEDIA CONTACTS
Image Sept
Leslie Jung-Isenwater / Sergio de la Calle / Florence Coupry
eureking@image7.fr
+33 (0)1 53 70 74 70
Disclaimer
On June 6, 2023, J.P. Morgan terminated its association with eureKING and waived any fees and compensation in connection with such association. On the same day, J.P. Morgan also waived its entitlement to the payment of any deferred compensation in connection with its role as underwriter in eureKING's initial public offering. J.P. Morgan has informed eureKING that it is not responsible for any portion hereof.
About eureKING
Founded in March 2022, eureKING is a French SPAC (Special Purpose Acquisition Company) formed with the aim of acquiring European companies in the field of cutting-edge biomanufacturing, with the ambition of creating a leading bio CDMO in Europe capable of meeting the growing outsourcing needs of this industry. eureKING has chosen to focus on three highly specialized and strategic segments of the biopharmaceutical industry: the production of biologics, in particular new generations of monoclonal antibodies or complex proteins, the production of cell and gene therapies and the production of live biotherapeutics (with applications in the microbiome).
With a €150 million capital raising in May 2022, eureKING is led by an international management team of experienced healthcare industry talent, 100% dedicated to the SPAC project and its development strategy. eureKING is supported by a Board of Directors with complementary pharmaceutical and financial expertise to achieve its goal of developing and promoting the promising biomanufacturing sector in Europe on an international scale.
eureKING is listed on the professional compartment of Euronext Paris since May 12, 2022.
www.eureking.com
The shareholders of eureKING are called to approve the early dissolution of the Company at the extraordinary general meeting to be held on November 28, 2023 (the "Extraordinary General Meeting"). At the same meeting, shareholders will also be asked to vote on the acknowledgment that the Founders' Warrants (BSAR A) and Market Warrants (BSAR B) have lapsed, in accordance with their terms and conditions and on the delisting of the Company's financial instruments admitted to trading on the regulated market of Euronext Paris.
In the absence of an Initial Business Combination on the Initial Business Combination Deadline1, the Founders' Warrants (BSAR A) and the Market Warrants (BSAR B) will be definitively deprived of any right of exercise and will expire worthless in the context of the forthcoming liquidation, if approved by the shareholders, in accordance with their respective terms and conditions, the Company's articles of association and the IPO Prospectus.
As a result of the Company's early dissolution, and assuming a favourable vote by the shareholders, (i) the listing of the Market Warrants (BSAR B) and the Market Shares (actions de préférence de catégorie B) will be suspended as from November 28, 2023, and (ii) the Market Warrants (BSAR B) and the Market Shares (actions de préférence de catégorie B) will be delisted from the regulated market by Euronext Paris as of November 29, 2023, it being specified that the Market Shares (actions de préférence de catégorie B) will remain admitted to Euroclear France. Therefore, as from this date, no further financial instruments of the Company will be admitted to trading on Euronext Paris.
MEDIA CONTACTS
Image Sept
Leslie Jung-Isenwater / Sergio de la Calle / Florence Coupry
eureking@image7.fr
+33 (0)1 53 70 74 70
Disclaimer
On June 6, 2023, J.P. Morgan terminated its association with eureKING and waived any fees and compensation in connection with such association. On the same day, J.P. Morgan also waived its entitlement to the payment of any deferred compensation in connection with its role as underwriter in eureKING's initial public offering. J.P. Morgan has informed eureKING that it is not responsible for any portion hereof.
About eureKING
Founded in March 2022, eureKING is a French SPAC (Special Purpose Acquisition Company) formed with the aim of acquiring European companies in the field of cutting-edge biomanufacturing, with the ambition of creating a leading bio CDMO in Europe capable of meeting the growing outsourcing needs of this industry. eureKING has chosen to focus on three highly specialized and strategic segments of the biopharmaceutical industry: the production of biologics, in particular new generations of monoclonal antibodies or complex proteins, the production of cell and gene therapies and the production of live biotherapeutics (with applications in the microbiome).
With a €150 million capital raising in May 2022, eureKING is led by an international management team of experienced healthcare industry talent, 100% dedicated to the SPAC project and its development strategy. eureKING is supported by a Board of Directors with complementary pharmaceutical and financial expertise to achieve its goal of developing and promoting the promising biomanufacturing sector in Europe on an international scale.
eureKING is listed on the professional compartment of Euronext Paris since May 12, 2022.
www.eureking.com
